Yanling Wang

Yanling Wang

Auto-generated profile, based on publicly available information

Yanling Wang

Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Jianggan District, Hangzhou, Zhejiang 310016, People's Republic of China,

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
MTMengting Tong
Mengting Tong
JWJing Wang
Jing Wang
WHWenting He
Wenting He
YWYanling Wang
Yanling Wang
HPHongming Pan
Hongming Pan
HZHongliang Zhang
Hongliang Zhang
The development of immune checkpoint inhibitors represented by PD-1 and PD-L1 has provided new hope for the treatment of advanced cancer patients. However, there are no effective predictive biomarkers, which have caused many limitations to the clinical application of immune checkpoint inhibitors. This paper combines recent domestic and international research as well as clinical trials to discuss the current status and progress of PD-L1 expression as a biomarker for tumor immunotherapy and also to discuss whether tumor mutation burden, tumor-infiltrating lymphocytes, tumor cell gene expression profiling, or peripheral blood markers would be a potential predictive biomarker for novel tumor immunotherapy. So, a brief review on this hot topic of predictive biomarkers for tumor immunotherapy is conducted.